SAIPARENT · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
India Ratings & Research Private Limited, the monitoring agency appointed for Sai Parenterals' IPO, has filed its first quarterly report covering the period ending March 31, 2026. The IPO, which raised INR 2,850 million (fresh issue) via a 72,70,408 equity share offering at ₹392 per share, concluded on March 27, 2026. As of quarter-end, the entire IPO proceeds of ₹2,850 million remain unutilized and lying in an Escrow account with Axis Bank. The monitoring agency confirms there is no deviation from the stated objects of the issue and no material changes to the means of finance. Planned utilization covers capacity expansion (₹1,107.95M), new R&D Centre (₹180.23M), repayment of borrowings (₹143.02M), working capital (₹330M), repayment of bridge/term loan for the Singapore subsidiary's acquisition of Noumed Pharmaceuticals (₹356.41M), and general corporate purposes (₹447.40M). All projects are ongoing with a targeted completion in Fiscal 2027.
The full unutilization of IPO proceeds at this early stage is normal post-IPO behavior. No red flags were raised by the monitoring agency, which is a positive signal for investors concerned about fund deployment. Shareholders can track progress in future quarterly reports.